<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR520.html">Part 520
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 520.1443  Milbemycin oxime and lufenuron.
                            </h3>
                            <p class="depth1"><em>(a)</em> Specifications--</p><p class="depth2"><em>(1)</em> Tablets containing: 2.3 milligrams (mg)  milbemycin oxime and 46 mg lufenuron, 5.75 mg milbemycin oxime and 115  mg lufenuron, 11.5 mg milbemycin oxime and 230 mg lufenuron, or 23 mg  milbemycin oxime and 460 mg lufenuron.</p><p class="depth2"><em>(2)</em> Flavored tablets containing: 2.3 mg milbemycin oxime and 46 mg  lufenuron, 5.75 mg milbemycin oxime and 115 mg lufenuron, 11.5 mg  milbemycin oxime and 230 mg lufenuron, or 23 mg milbemycin oxime and 460  mg lufenuron.</p><p class="depth1"><em>(b)</em> Sponsor. See No. 058198 in Sec. 510.600(c) of this chapter.</p><p class="depth1"><em>(c)</em> [Reserved]</p><p class="depth1"><em>(d)</em> Conditions of use--</p><p class="depth2"><em>(1)</em> Dogs--</p><p class="depth3"><em>(i)</em> Amount. 0.5 mg milbemycin oxime  and 10 mg lufenuron per kilogram of body weight, once a month.</p><p class="depth3"><em>(ii)</em> Indications for use--</p><p class="depth4"><em>(A)</em> For use in dogs and puppies for the  prevention of heartworm disease caused by Dirofilaria immitis, for  prevention and control of flea populations, for control of adult  Ancylostoma caninum (hookworm), and for removal and control of adult  Toxocara canis, Toxascaris leonina (roundworm), and Trichuris vulpis  (whipworm) infections.</p><p class="depth4"><em>(B)</em> The concurrent use of flavored milbemycin oxime and lufenuron  tablets described in paragraph (a)(2) of this section as in paragraph  (d)(1)(ii)(A) of this section with nitenpyram tablets as in Sec.  520.1510(d)(1) of this chapter is indicated to kill adult fleas and  prevent flea eggs from hatching.</p><p class="depth3"><em>(iii)</em> Limitations. Federal law restricts this drug to use by or on  the order of a licensed veterinarian.</p><p class="depth2"><em>(2)</em> [Reserved]  [62 FR 28629, May 27, 1997, as amended at 63 FR 41190, Aug. 3, 1998; 68  FR 51905, Aug. 29, 2003. Redesignated at 77 FR 47512, Aug. 9, 2012]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
